Welcome to Iris Biotech
For better service please confirm your country and language we detected.
Währung
EUR
Schneller Kontakt
Bitte senden Sie mir mehr Informationen über
Paclitaxel
Synonyme: Taxol
- Art-Nr.:LS-1047
- CAS Nr.:33069-62-4
- Formel:C47H51NO14
- Molare Masse:853,93 g/mol
Startet von 325,00 €
description
Paclitaxel, discovered in 1967, is a mitotic inhibitor used in cancer chemotherapy. It is used to treat patients with lung, ovarian, breast, head and neck cancer, advanced forms of Kaposi's sarcoma, and is also used for the prevention of restenosis. Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division.
While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. Side effects such as unusual bruising or bleeding, pain/redness/swelling at the injection site, change in normal bowel habits for more than two days, fever, chills, cough, sore throat, difficulty swallowing, dizziness, shortness of breath, severe exhaustion, skin rash, facial flushing, female infertility by ovarian damage and chest pain can occur.
Combination therapy is a new approach to take advantage of Paclitaxel’s anti-cancer properties and diminish its side effects. PGA (Poly(Glutamic Acid)) is an ideal carrier to be
loaded with Paclitaxel and corresponding drugs as published in the following examples:
The combination of anti-angiogenic therapy with cytotoxic one offers a promising therapeutic approach. A polyglutamic acid (PGA)-Paclitaxel-E-[c(RGDfK)2] conjugate has been developed.1,2 The combination of E-[c(RGDfK)2] with Paclitaxel in the same PGA mainchain enhanced the effects previously seen for PGA-PTX alone by utilizing: (i) the additional
active targeting to the avß3 integrin and (ii) its anti-angiogenic character. PGA-Paclitaxel-E-[c(RGDfK)2] displayed a potent anti-angiogenic therapy, revealed by several
well-established in vitro assays. Mice bearing orthotopic mammary tumors demonstrated preferential tumor accumulation of the RGD-bearing conjugate, leading to enhanced antitumor
efficacy and a marked decrease in toxicity compared with free Paclitaxel. 1,2
references
A. Eldar-Boock , K. Miller, J. Sanchis, R. Lupu, M.J.Vicent, R. Satchi-Fainaro. Biomaterials 2011; 132(15): 3862-74.
R. Satchi-Fainaro and M.J. Vicent; WO/2009/141826 .
Saville, M.W.; Lietzau, J.; Pluda, J.M.; Wilson, W.H.; Humphrey, R.W.; Feigel, E.; Steinberg, S.M.; Broder, S. et al. The Lancet 1995; 346(8966): 26-8.
doi:10.1016/S0140-6736(95)92654-2.
Ozcelik, Bulent; Turkyilmaz, Cagdas; Ozgun, Mahmut Tuncay; Serin, Ibrahim Serdar; Batukan, Cem; Ozdamar, Saim; Ozturk, Ahmet; Fertility and Sterility 2010; 93(5): 1609-14.
doi:10.1016/j.fertnstert.2009.02.054.
Bulk oder Großmengen-Bestellung?
Sie benötigen größere Mengen für Ihre Entwicklung oder Produktion?
Benötigen Sie weitere Informationen über dieses Produkt?
kontaktieren Sie uns
Verwandte Produkte
Produkte, die Sie auch interessieren könnten!
